- $9.77bn
- $9.55bn
- $507.44m
Brief: Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes In Keratoconus
US RESEARCH ROUNDUP-Boeing, Twilio, WP Carey
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Glaukos Corp reports results for the quarter ended June 30 - Earnings Summary
Glaukos Q2 sales jump 50%; raises net sales forecast
Brief: Glaukos Q2 Sales USD 185.6 Million Vs. IBES Estimate USD 150.9 Million
Brief: Glaukos Announces Completion Of Patient Enrollment In Phase 2 Study Of Glk-321 For Demodex Blepharitis
U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta
Glaukos raises full-year sales forecast after Q1 beat
Brief: Glaukos Q1 Sales USD 150.6 Million Vs. IBES Estimate USD 136.9 Million
Glaukos Q4 revenue rises on glaucoma sales
Brief: Glaukos Q4 Adjusted Net Income USD -16.4 Million Vs. IBES Estimate USD -12.1 Million
U.S. STOCKS ON THE MOVE-Applied Materials, Sherwin-Williams, Caterpillar
U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker International
Glaukos rises as FDA allows repeat use of glaucoma implant
Brief: Glaukos Announces US FDA Approval Of NDA Supplement Allowing For Re-Administration Of Idose® Tr
Glaukos slumps after reaffirming annual net sales forecast
Brief: Glaukos Announces Preliminary, Unaudited Fourth Quarter Results